Lantheus Holdings, Inc. (LNTH) on Decifer

Decifer ranks LNTH number 186 of 276 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 12% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is expected to grow about 12% a year, profits are expected to grow 17%, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• And it returns cash to shareholders.
• Revenue expected to grow about 12% a year and momentum of 22 out of 35 are encouraging, but no worldview role holds it to the middle.

The current read

The evidence on LNTH lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Lantheus Holdings, Inc. operates in drug manufacturers - specialty & generic. That places it inside the Healthcare, Biotech & Devices story.

Read the full LNTH research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.